Maarten R. Hillen

Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial

Eefje Hanna Martine van der Heijden, Sofie Liny Marie Blokland, Maarten R. Hillen et al. · The Lancet Rheumatology · 2020 · 91 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis

Eleni Chouri, Nila H. Servaas, Cornelis P. J. Bekker et al. · Journal of Autoimmunity · 2018 · 82 citations · Full text

Medicine, Molecular Medicine, Pathobiology +17

Plasmacytoid DCs From Patients With Sjögren's Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production

Maarten R. Hillen, Aridaman Pandit, Sofie L. M. Blokland et al. · Frontiers in Immunology · 2019 · 62 citations · Full text

Life Sciences, Immunology, Pathology +17

Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome

Maarten van der Kroef, Lucas L. van den Hoogen, Jorre S. Mertens et al. · European Journal of Immunology · 2019 · 61 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjögren's Syndrome: Potential New Axis in Lymphoid Neogenesis

Sofie L. M. Blokland, Maarten R. Hillen, Aike A. Kruize et al. · Arthritis & Rheumatology · 2017 · 57 citations

Life Sciences, Immunology, Pathobiology +17